Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

981
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
981
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

710
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
710
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

327
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
327

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Nature communications·2026
Same author

Upadacitinib Achieved Rapid Response in Biologic-Refractory Immune Checkpoint Inhibitor-Related Enterocolitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

A Multidisciplinary Approach to Checkpoint Inhibitor Adverse Reactions.

The journal of allergy and clinical immunology. In practice·2026
Same author

YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.

Future oncology (London, England)·2026
Same author

YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Before the Race Even Starts: Early Intervention to Prevent Long-Term Late Effects From Childhood Cancer Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
See all related articles

Related Experiment Video

Updated: Apr 12, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.3K

Managing immune checkpoint-blocking antibody side effects.

Michael A Postow1

  • 1From the Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 21, 2015
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors like anti-CTLA-4 and anti-PD-1/PD-L1 antibodies treat cancer but can cause immune-related adverse events (irAEs). This review details irAEs and management strategies for these effective cancer therapies.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K

Related Experiment Videos

Last Updated: Apr 12, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.3K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Immune checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1 are crucial in cancer therapy.
  • Ipilimumab (anti-CTLA-4) and nivolumab/pembrolizumab (anti-PD-1/PD-L1) are FDA-approved for various malignancies.
  • These therapies enhance the immune system's anti-cancer response.

Purpose of the Study:

  • To describe the side-effect profile of immune checkpoint-blocking antibodies.
  • To provide management strategies for immune-related adverse events (irAEs).
  • To review the clinical use of anti-CTLA-4 and anti-PD-1/PD-L1 therapies.

Main Methods:

  • Review of side-effect profiles associated with anti-CTLA-4 and anti-PD-1/PD-L1 antibodies.
  • Discussion of common immune-related adverse events (irAEs) across organ systems.
  • Summary of current treatment approaches for irAEs, including immunosuppression.

Main Results:

  • Immune checkpoint inhibitors are associated with immune-related adverse events (irAEs).
  • irAEs can affect multiple organ systems, including dermatologic, gastrointestinal, and hepatic.
  • Temporary immunosuppression with agents like corticosteroids is an effective management strategy.

Conclusions:

  • Understanding and managing irAEs is essential for the safe and effective use of immune checkpoint inhibitors.
  • Prompt recognition and treatment of irAEs can mitigate toxicity and maintain therapeutic benefits.
  • Continued research into irAE management will optimize cancer immunotherapy outcomes.